


AMENDMENTS TO THE CLAIMS

1. (Previously presented) A compound of the formula:



I

wherein **M** represents a group of Formula II:



wherein

(i) Z and W independently are $>\text{C}=\text{O}$, $>\text{CH}_2$, $>\text{CH}-\text{NR}_t\text{R}_s$, $>\text{N}-\text{R}_\text{N}$ or $>\text{C}=\text{N}-\text{R}_\text{M}$, wherein

R_t and R_s independently are hydrogen or alkyl;


R_M is hydroxy, alkoxy, substituted alkoxy or OR^P ;

R_N is hydrogen, R^P , alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, or $\text{C}(\text{X})-\text{NR}_t\text{R}_s$; wherein X is $=\text{O}$ or $=\text{S}$;

provided that Z and W cannot both simultaneously be, $>\text{C}=\text{O}$, $>\text{CH}_2$, $>\text{CH}-\text{NR}_t\text{R}_s$, $>\text{N}-\text{R}_\text{N}$, $>\text{C}=\text{N}-\text{R}_\text{M}$ or a bond;

(ii) U and Y independently are hydrogen, halogen, alkyl, or hydroxyalkyl;

- (iii) R¹ is hydroxy, OR^p, -O-S² group or an =O;
(iv) S¹ is a sugar moiety of Formula III:



III


wherein

R⁸ and R⁹ are both hydrogen or together form a bond, or R⁹ is hydrogen and R⁸ is -N(CH₃)R^y, wherein

R^y is R^p, R^z or -C(O)R^z, wherein R^z is hydrogen or alkyl or alkenyl or alkynyl or cycloalkyl or aryl or heteroaryl or alkyl substituted with C₂-C₇-alkyl, C₂-C₇-alkenyl, C₂-C₇-alkynyl, aryl or heteroaryl;

R^{10} is hydrogen or R^p ;

S² sugar moiety of Formula IV:




IV

wherein

$R^{3'}$ is hydrogen or methyl;

R¹¹ is hydrogen, R^p, or O-R¹¹ is a group that with R¹² and with C/4" carbon atom forms a >C=O or epoxy group;

R^{12} is hydrogen or a group that with $O-R^{11}$ group and with $C/4''$ carbon



X

wherein

R^a and R^b independently represents, hydrogen or halogen;

R^c is hydroxy, alkoxy, alkyl, thiocarbamoyl, carbamoyl or a valence-bond;

R^d and R^e independently represents: hydrogen, hydroxy, methyl or C₁-C₄-alkoxy or each are a group that forms a 1,3-dioxolane ring with the other or a valence bond;

R^f is hydrogen, hydroxy, chloro, or forming a keto group with the carbon atom it is attached to;


R^j is hydrogen or halogen;

or a pharmaceutically acceptable salt or solvate thereof;

wherein


L is a linker molecule to which each of M and S are covalently linked.

2. (Currently amended) A compound of the Formula I:



I

wherein **M** represents a group of Formula II:



wherein


(i) Z and W independently are $>C=O$, $>CH_2$, $>CH-NR_tR_s$, $>N-R_N$ or $>C=N-R_M$, wherein

R_t and R_s independently are hydrogen or alkyl;


R_M is hydroxy, alkoxy, substituted alkoxy or OR^p ;

R_N is hydrogen, R^p , alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, or $-C(X)-NR_tR_s$; wherein X is $=O$ or $=S$;

provided that Z and W cannot both simultaneously be, $>C=O$, $>CH_2$, $>CH-NR_tR_s$, $>N-R_N$, $>C=N-R_M$ or a bond;



- (ii) U and Y independently are hydrogen, halogen, alkyl, or hydroxyalkyl;
- (iii) R¹ is hydroxy, OR^p, -O-S² group or an =O;
- (iv) S¹ is a sugar moiety of Formula **III**:




wherein

R⁸ and R⁹ are both hydrogen or together form a bond, or R⁹ is hydrogen and R⁸ is -N(CH₃)R^y, wherein

R^y is R^p, R^z or -C(O)R^z, wherein R^z is hydrogen or alkyl or alkenyl or alkynyl or cycloalkyl or aryl or heteroaryl or alkyl substituted with C₂-C₇-alkyl, C₂-C₇-alkenyl, C₂-C₇-alkynyl, aryl or heteroaryl;

R^{10} is hydrogen or R^p ;

S² sugar moiety of Formula IV:



IV

wherein

R^{3'} is hydrogen or methyl;

R¹¹ is hydrogen, R^p, or O-R¹¹ is a group that with R¹² and with C/4" carbon atom forms a >C=O or epoxy group;

R¹² is hydrogen or a group that with O-R¹¹ group and with C/4" carbon atom forms a >C=O or epoxy group;

(vi) R^2 is hydrogen, hydroxy, OR^p or alkoxy ;

(vii) A is hydrogen or methyl;

(viii) B is methyl or epoxy;

(ix) E is hydrogen or halogen;

R³ is hydroxy, OR^p, alkoxy or R³ is a group that with R⁵ and with C/11 and C/12 carbon atoms forms a cyclic carbonate or carbamate, or if W or Z is >N-R_N R³ is a group that with W or Z forms a cyclic carbamate;

(xi) R^4 is C₁-C₄ alkyl;

(xii) R⁵ is hydrogen, hydroxy, OR^p, C₁-C₄ alkoxy, or a group that with R³ and with C/11 and C/12 carbon atoms forms a cyclic carbonate or carbamate;

(xiii) R^6 is hydrogen or C_1 - C_4 -alkyl;


wherein **M** has a linkage site through which it is linked to **S** *via* linking group **L**; provided that the linkage site being at one or more of the following:

- a) any reactive hydroxy, nitrogen, or epoxy group located on S^1 , S^2 , or an aglycone oxygen if S^1 and/or S^2 is cleaved off;
- b) a reactive $>N-R_N$ or $-NR_4R_5$ or oxo group located on Z or W;
- c) a reactive hydroxy group located at any one of R^1 , R^2 , R^3 , and R^5 ;

d) any other group that can be first derivatized to a hydroxy or -NR_tR_s group and

R^p is hydroxyl or amino protective group; and

L represents a group of Formula VA or of Formula VB:



R^c is hydroxy, alkoxy, alkyl, thiocarbamoyl, carbamoyl or a valence-bond;
 R^d and R^e independently represents: hydrogen, hydroxy, methyl or C_1 - C_4 -alkoxy or each are a group that forms a 1,3-dioxolane ring with the other or a valence bond;
 R^f is hydrogen, hydroxy, chloro, or forming a keto group with the carbon atom it is attached to;
 R^j is hydrogen or halogen;
or a pharmaceutically acceptable salt or solvate thereof.

3. (Canceled).
4. (Canceled)
5. (Previously presented) The compound according to claim 2 wherein
Z is $>NR_N$, wherein R_N is hydrogen or a methyl group;
W is $>CH_2$;
B is methyl;
E is hydrogen;
 R^2 is hydroxy;
A is methyl;
 S^1 group represents a group of Formula **III** wherein
 R^8 is selected from: hydrogen, amino, *N*-methylamino, *N,N*-dimethylamino,
N-methyl-*N*-(C_2 - C_4)-alkylamino, *N*-methyl-*N*-methylcarbonylamino,
N-methyl-*N*-benzylamino, *N*-methyl-*N*-cyclohexylamino;
 R^9 and R^{10} are hydrogen;
 R^1 is $O-S^2$ wherein S^2 represents a group of Formula **IV** wherein R^{11} and R^{12} are hydrogen and R^{13} is methyl;
U is hydrogen;
Y is methyl;

R⁴ is methyl;

R⁶ is ethyl;

R⁵ is hydroxy or a group that with R³ and with C/11 and C/12 carbon atoms forms a cyclic carbonate bridge;

R³ is hydroxy or a group that with R⁵ and with C/11 and C/12 carbon atoms forms a cyclic carbonate bridge;

provided that the linkage is through the nitrogen of Z at N/9a position or through the oxygen of R³ at C/11 position.

6. (Previously presented) The compound according to claim 2 wherein Z is selected from >N-H, >N-CH₃, >N-C(O)NHR^x, wherein R^x is isopropyl;
- W is >C=O or >CH₂ provided that when Z is >N-CH₃ W cannot be >C=O;
- B is methyl;
- E is hydrogen;
- A is methyl;
- R² is hydroxy or methoxy;
- S¹ group represents a group of Formula **III** wherein
- R⁸ is selected from: amino, C₁-C₆-alkylamino, C₁-C₆-dialkylamino;
- R⁹ and R¹⁰ are hydrogen;
- R¹ is O-S² wherein S² represents a group of Formula **IV** wherein R¹¹ is hydrogen or
- O-R¹¹ is a group that with R¹² and with C/4" carbon atom forms a >C=O or epoxy group; R¹² is hydrogen or a group that with O-R¹¹ group and with C/4" carbon atom forms a >C=O or epoxy group; R¹³ is methyl;
- U is hydrogen;
- Y is methyl;
- R³ is hydroxy;
- R⁴ is methyl;

R^5 is hydroxy or methoxy;

R^6 is ethyl;

provided that the linkage is through the nitrogen of R^8 at C/3', through the oxygen of R^2 at C/6 or through the carbon of R^{12} or through the oxygen of R^{11} both at C/4".

7. (Previously presented) The compound according to claim 2 wherein

R^a and R^b independently represents, hydrogen or halogen;

R^d is hydrogen or hydroxy;


R^e is methyl;

R^f is hydroxy;

R_j is hydrogen


provided that the linkage is through the valence bond R^k .

8. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

11. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a
pharmaceutically acceptable salt or solvate thereof.

12. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a
pharmaceutically acceptable salt or solvate thereof.

13. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

14. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

15. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

16. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a
pharmaceutically acceptable salt or solvate thereof..

17. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a
pharmaceutically acceptable salt or solvate thereof.

18. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

19. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a
pharmaceutically acceptable salt or solvate thereof.

20. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof..

23. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

24. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a
pharmaceutically acceptable salt or solvate thereof.

25. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

26. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

27. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

28. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

29. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a
pharmaceutically acceptable salt or solvate thereof.

30. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a
pharmaceutically acceptable salt or solvate thereof.

33. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

34. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

35. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a
pharmaceutically acceptable salt or solvate thereof.

36. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a
pharmaceutically acceptable salt or solvate thereof.

39. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

40. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

43. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

44. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

45. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

46. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

47. (Currently amended) A compound of the formula




~~and pharmaceutically acceptable salts and solvates thereof~~ or a pharmaceutically acceptable salt or solvate thereof.

48. (Currently amended) A process for the preparation for a compound of Formula I:



wherein **M** represents a group of Formula II:



wherein

(i) Z and W independently are $>\text{C}=\text{O}$, $>\text{CH}_2$, $>\text{CH}-\text{NR}_t\text{R}_s$, $>\text{N}-\text{R}_\text{N}$ or $>\text{C}=\text{N}-\text{R}_\text{M}$, wherein

R_t and R_s independently are hydrogen or alkyl;

R_M is hydroxy, alkoxy, substituted alkoxy or OR^P ;


R_N is hydrogen, R^P , alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, or $-\text{C}(\text{X})-\text{NR}_t\text{R}_s$; wherein X is $=\text{O}$ or $=\text{S}$;

provided that Z and W cannot both simultaneously be, $>\text{C}=\text{O}$, $>\text{CH}_2$, $>\text{CH}-\text{NR}_t\text{R}_s$, $>\text{N}-\text{R}_\text{N}$, $>\text{C}=\text{N}-\text{R}_\text{M}$ or a bond;


(ii) U and Y independently are hydrogen, halogen, alkyl, or hydroxyalkyl;

(iii) R^1 is hydroxy, OR^P , $-\text{O}-\text{S}^2$ group or an $=\text{O}$;

(iv) S^1 is a sugar moiety of Formula **III**:




represented by Formula **VIId**:




VIId

b) for a compound represented by Formula **I**, where X^2 is $-\text{OC}(\text{O})-$, by reacting a compound of Formula **V** and a hydroxyl group of a macrolide represented by Formula **VIe**:




VIe

c) for a compound represented by Formula **I**, wherein X^1 is $-\text{OC}(\text{O})-$, Q is NH and X^2 is $-\text{NHC}(\text{O})-$, by reacting a macrolide represented by:




and a free amino group of the compound represented by Formula **IVc**:



IVc


d) for a compound represented by Formula **I**, where X^1 is $-\text{OC}(\text{O})\text{NH}-$ and X^2 is $-\text{NHC}(\text{O})-$, by reacting a macrolide represented by Formula **VII** and

a free amino group of Formula **IVc**:




VII

e) for a compound represented by Formula **I**, X^1 is $-\text{CH}_2-$, Q is $-\text{NH}-$ and X^2 is $-\text{NHC(O)}-$, by reacting a macrolide represented by Formula **Va** and a compound of Formula **V**:




Va


f) compound of Formula **I** by reacting a macrolide represented by Formula **VIh** or by Formula **VIg** or by Formula **VIh** having a leaving group L^2



with a free carboxyl acid of steroid represented by Formula **IVb**




g) for a compound represented by Formula I, wherein X¹ is -OC(O)-, Q is NH and X² is -NH- by reacting a macrolide represented by:



VId

and a steroid subunit having a -C=C- bond represented by Formula **Sb**:



following by modification of R^c group.

49. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 1 ~~and~~ or a pharmaceutically acceptable ~~salts~~ salt or solvate thereof as well as pharmaceutically acceptable diluent or carrier.
50. (Currently Amended) A method of treatment of inflammatory diseases, disorders ~~and~~ or conditions characterized by or associated with an undesirable inflammatory immune response, and all diseases and conditions induced by or associated with an excessive secretion of TNF- α and IL-1 which comprises administering to a subject in need of treatment a therapeutically effective amount of a compound according to claim 1.

inflammatory immune response, and all diseases and conditions induced by or associated with an excessive secretion of TNF- α and IL-1 which comprises administering to a subject in need of treatment a therapeutically effective amount of a compound according to claim 2.

57. (New) A method of treating inflammatory conditions or immune or anaphylactic disorders associated with infiltration of leukocytes into inflamed tissue in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a compound according to claim 2.
58. (New) The method according to claim 57, wherein inflammatory conditions and immune disorders are selected from the group consisting of asthma, adult respiratory distress syndrome, bronchitis, and cystic fibrosis.
59. (New) A method according to claim 57, wherein said inflammatory conditions and immune disorders are selected from the group consisting of inflammatory conditions or immune disorders of the lungs, joints, eyes, bowel, skin, and heart.
60. (New) A method according to claim 57, wherein said inflammatory conditions and immune disorders are selected from the group consisting of asthma, adult respiratory distress syndrome, bronchitis, cystic fibrosis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, uveitis, conjunctivitis, inflammatory bowel conditions, Crohn's disease, ulcerative colitis, distal proctitis, psoriasis, eczema, dermatitis, coronary infarct damage, chronic inflammation, endotoxin shock, and smooth muscle proliferation disorders.